Control study on perospirone and quetiapine in the treatment of senile dementia patients with behavioral and psychological symptoms

Abstract

Abstract: AIM: To compare the clinical efficacy and safety of perospirone and quetiapine in the treatment of senile dementia patients with behavioral and psychological symptoms. METHODS: 106 cases of senile dementia patients were randomly divided into the perospirone group and the quetiapine group. The efficacy and adverse reaction were evaluated by Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Cohen-Mansfield Agitation Inventory (CMAI), Mini-Mental State Examination (MMSE), Activity of Daily Life (ADL) and Treatment Emergent Symptoms Scale (TESS) in baseline and after 12 weeks of treatment. RESULTS: After 12 weeks of treatment, the efficiacy rate was 82.0% in perospirone group and 85.7% in quetiapine group.There were no significant differences between the two groups (P>0.05). The scores of BEHAVE-AD and other factors were significantly decreased after the 12 weeks of treatment with perospirone, especially factors of hallucinations, behavior disorders and aggressive behavior (P<0.01). The MMSE and ADL scores of two groups after the 12 weeks of treatment were higher than the scores before treatment, but there were no significant differences between before and after treatment. The adverse reactions of perospirone group was lower than that of quetiapine group, but there were no significant differences between the two groups. CONCLUSION: Compared with quetiapine, perospirone has similar efficacy and safety in the treatment of behavioral and psychological symptoms of senile dementia, and fewer adverse reactions were found in perospirone group.

Key words: Perospirone, Quetiapine, Senile dementia patient, Behavioral and psychological symptom

CLC Number:

R749

ZHOU Yong, WANG Yan, LIU Li-na. Control study on perospirone and quetiapine in the treatment of senile dementia patients with behavioral and psychological symptoms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 90-94.

References

[1] O'Connor DW.Epidemiology of behavioral and psychological symptoms of dementia[J]. Int Psychogeritia, 2000, 12(S1): 41-45.
[2] Schneider LS, Pollock VE, Lyness SA.A meta-analysis of controlled trials of neuroleptic treatment in dementia[J]. J Am Geriatr Soc, 1990, 38(5):553-563.
[3] 伍毅, 俞玲俐, 李秀英, 等. 利培酮与奋乃静治疗老年期痴呆精神症状的对照研究[J]. 四川精神卫生, 2005, 18(2):94-96.
[4] 盛建华, 高之旭, 陈美娟, 等. 利培酮与氟哌啶醇随机双盲治疗痴呆的行为和精神症状[J]. 中国新药与临床杂志, 2004, 23(6):359-361.
[5] 李冉冉, 高静芳, 侯群. 喹硫平治疗老年期痴呆患者精神行为症状的临床观察[J]. 上海精神医学, 2009, 21(6):355-362.
[6] 胡恒章. 喹硫平与利培酮治疗老年精神分裂症的对照研究[J] . 中国临床药理学与治疗学, 2010, 15(2):203-205.
[7] 侯振成. 喹硫平治疗老年期痴呆患者行为和心理症状的临床观察[J]. 中国民康医学, 2006, 18(8):643-645.
[8] 陈建, 冯锋, 吉中孚, 等. 喹硫平治疗老年期痴呆伴行为和精神障碍对照研究[J]. 临床精神医学杂志, 2008, 18(4):259-260.
[9] 张明廉, 袁国桢, 姚建军, 等. 喹硫平和氟哌啶醇治疗老年痴呆精神行为症状的对照研究[J]. 中国新药与临床杂志, 2006, 25(9):706-708.
[10] 涂继莹, 左笑丛, 李焕德. 非典型抗精神病药——哌罗匹隆[J]. 中国临床药理学杂志, 2007, 23(2):157-160.
[11] 李冠军, 李华芳, 顾牛范. 新型非典型抗精神病药——哌罗匹隆(perospirone)[J]. 上海精神医学, 2001, 13(3):163-l65.
[12] Sato S, Mizukami K, Moro K, et al.Efficacy of perospirone in the management of aggressive behavior associated with dementia[J] Prog Neuropsychopharmacolo Biol Psychiatry, 2006, 30(4):679-683.
[13] Sato S, Mizukami K, Moro K, et al.Beneficial effects of perospironeon aggressive behavior associated with dementia[J]. Psychiatr Clin Neurosci, 2006; 60(1):106-109.
[14] Takahashi Y, Kusumi I, Ishikane T, et al.In vivo occupation of dopamine D₁, D₂ and serotonin (5-HT)_2A receptors by sertindole in the rat brain[J]. J Psychiatry Neurosci, 1998, 23(3): 157-162.